UBS Group
MANE icon

UBS Group’s Veradermics Inc MANE Stock Holding History

UBS Group’s Portfolio MANE Stock Details MANE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$70.4M Sell
580,858
-89,869
-13% -$9.8M 0.01% 1377
2026
Q2 		$82.5M Buy
670,727
+323,652
+93% +$30.3M 0.01% 1273
2026
Q1 		$21.9M Buy
+347,075
New +$17.5M ﹤0.01% 2493

Other funds holding MANE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

UBS Group's MANE Position: Q3 2026 in Review

UBS Group reduced its Veradermics Inc (MANE) stake by 13% in Q3 2026, selling an estimated $9.8M and leaving 580,858 shares worth $70.4M. The position accounts for 0.01% of the portfolio, ranked #1377.

UBS Group first reported a position in MANE in Q1 2026 and has held it in 3 quarters since. The position peaked at $82.5M in Q2 2026. 139 funds tracked by Wall St. Rank hold MANE as of Q3 2026.

  • UBS Group held 580,858 shares of Veradermics Inc worth $70.4M as of Q3 2026.
  • UBS Group sold 89,869 Veradermics Inc shares in Q3 2026, an estimated $9.8M.
  • Veradermics Inc made up 0.01% of UBS Group's portfolio in Q3 2026, its #1377 holding.
  • UBS Group first reported a position in Veradermics Inc in Q1 2026 and has held it in 3 quarters since.
  • UBS Group's Veradermics Inc position peaked at $82.5M in Q2 2026.
  • 139 funds tracked by Wall St. Rank held Veradermics Inc as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.